Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03319459 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT03319459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03319459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 18, 2018
Completion date
December 15, 2020
Enrollment
44 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, colorectal cancer, egfr positive solid tumor, head and neck squamous cell carcinoma, hepatocellular carcinoma, her2 positive gastric cancer, her2-positive breast cancer, melanoma, non small cell lung cancer, pancreatic cancer, renal cell carcinoma